Americord Funds Clinical Trial Investigating Umbilical Cord Blood Transplantation in Patients with Beta Thalassemia Major

Share Article

Funds Will Support Research Into Safety and Efficacy of Umbilical Cord Stem Cell Transplantations to treat Beta Thalassemia Major

Cord Blood Banking

Cord Blood - Americord

Americord Registry announced today that it has provided funding to Nanfang Hospital of Southern Medical University in Guangzhou, Guangdong, China. Funding will support research into the safety and efficacy of umbilical cord stem cell transplantations to treat Beta Thalassemia Major. Specifically, in this trial umbilical cord blood is used to reduce the occurrence of Graft-Versus-Host Disease in patients receiving haploidentical HSCT transplants to treat Beta Thalassemia Major.

Beta Thalassemia Major is a genetic blood disorder that involves the decreased production of normal adult hemoglobin. The condition results in a severe anemia that begins a few months after birth.

Americord’s donation of funds is part of the company’s corporate giving program, which was established to support research focused on the therapeutic uses of stem cells from umbilical cord blood, cord tissue, and placenta tissue.

“Americord is committed to supporting the advancement of stem cell technologies,” said Americord CEO Martin Smithmyer. “Our support of Dr. Chunfu Li’s trial at Nanfang Hospital is a manifestation of that desire.”

The study at Nanfang Hospital began in April 2014 and is anticipated to be complete by June 2015. It is registered with ClinicalTrials.gov in accordance with best practices and requirements of the U.S. Food and Drug Administration.

For more information about the clinical trial: http://1.usa.gov/1wv862c
About Americord Registry                        

Americord Registry is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord Registry's website at http://www.americordblood.com for more information. You may also find Americord Registry on Facebook and follow the company on Twitter.

###

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Raechel Sherwood
Follow us on
Visit website